- Capital Cube•12 days ago
Categories: Yahoo Finance Get free summary analysis Aeolus Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Aeolus Pharmaceuticals, Inc. – Cleveland BioLabs, Inc., MediciNova, Inc., Amgen Inc., Fate Therapeutics, Inc., Albany Molecular Research, Inc., CytRx Corporation, ProPhase Labs, Inc. and Omeros Corporation (CBLI-US, MNOV-US, ... Read more (Read more...)
- Marketwired•14 days ago
Aeolus Pharmaceuticals, Inc. , a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection, announced today financial results for the nine months ...
- PR Newswire•2 months agoStockNewsNow.com Publishes New SNNLive Video Interview with Aeolus Pharmaceuticals, Inc. Discussing Clinical Development and Milestones for 2016-2017
LOS ANGELES, July 7, 2016 /PRNewswire/ -- StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with David Cavalier, Chairman & CFO of Aeolus Pharmaceuticals, ...
Aeolus Pharmaceuticals Inc. (AOLS)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||0.18 - 0.20|
|52wk Range||0.18 - 0.23|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-4.79|
|Avg Vol (3m)||30,983|
|Dividend & Yield||N/A (N/A)|